- Email: [email protected]
CME Multiple Choice Questions
Continuing Medical Education CME Multiple Choice Questions
jsm_2404
1. The most established mechanism for priapism in sickle cell disease (SCD) patients is: a) Phosphodiesterase type 5 inhibitors (PDE5) dysregulation in penile tissue. b) Microvascular occlusion caused by sickling of deoxygenated red blood cells. c) Increased adenosine levels in penile tissue. d) High flow priapism following previous surgical treatments for ischemic priapism. 2. A PDE5 inhibitor is not recommended as an erectile dysfunction (ED) treatment option in a homozygous SCD patient because: a) It may increase the risk of vaso-occlusive crisis. b) It may worsen the patient’s pulmonary arterial hypertension. c) It is clinically not effective. d) Clinical trials demonstrated a greater risk of priapism. 3. The most effective therapy for ischemic priapism in SCD patients is: a) Hydration. b) Plasmapheresis.
2128
c) Pseudoephedrine tablets. d) Intracavernosal treatments (irrigation and evacuation of corporal blood; injection of alpha-adrenergic sympathomimetic agent). 4. Preventive strategies for stuttering priapism in SCD patients include all of the following EXCEPT: a) Hormonal therapies with gonadotropin-releasing hormone agonist or androgen receptor antagonist. b) Intracavernosal self-injection of phenylephrine. c) Penile prosthesis surgery. d) Polyethylene glycol-modified adenosine deaminase drug therapy. 5. In postpriapism ED patients: a) The only treatment option is penile prosthesis surgery. b) The most common cause is shunt fistula from previous shunt surgery. c) Conservative options (PDE5 inhibitors, vacuum device, intraurethral alprostadil, and intracavernosal injections) can sometimes be effective. d) Corporal fibrosis does not make penile prosthesis surgery more difficult.
Overall evaluation of the activity a. Excellent b. Very good c. Good d. Fair e. Poor
What degree of confidence do you have that you will apply your new learning in your practice? 100% 75% 50% 25% 0%
Was this activity responsive to your needs? Yes No
What one change will you make in your practice based on this new learning?
Was this activity relevant to your practice? Yes No Did this activity increase your knowledge and/or skills in delivering patient care? Yes No
List any topics you would find interesting and professionally relevant for future CME activities: This activity is designed for a maximum of 1 category 1 credit. You should only claim the number of credits you have earned based on the amount of time needed to complete this activity. How many credits are you claiming for this activity? a. 1 b. 0.75 c. 0.5 d. 0.25
Please indicate your current profession: 䊐 Physician 䊐 Nurse 䊐 Physician Assistant 䊐 Other Healthcare Professional 䊐 Nurse Practitioner 䊐 Other
Address 2:
Name:
Postal Code:
Institution:
Country:
Address 1:
Email Address:
City: State:
An online version of this activity is now available. If you wish to receive credit for this activity, please refer to the website: www.wileyblackwellcme.com. Alternatively, this page can be sent by fax to Blackwell Futura Media Services, at (781)-338-8325. If you do not receive your certificate within 30 days of submission, please contact David Kempe, Editorial Program Coordinator, at [email protected].
2128
J Sex Med 2011;8:2128
jsm_2404
1. The most established mechanism for priapism in sickle cell disease (SCD) patients is: a) Phosphodiesterase type 5 inhibitors (PDE5) dysregulation in penile tissue. b) Microvascular occlusion caused by sickling of deoxygenated red blood cells. c) Increased adenosine levels in penile tissue. d) High flow priapism following previous surgical treatments for ischemic priapism. 2. A PDE5 inhibitor is not recommended as an erectile dysfunction (ED) treatment option in a homozygous SCD patient because: a) It may increase the risk of vaso-occlusive crisis. b) It may worsen the patient’s pulmonary arterial hypertension. c) It is clinically not effective. d) Clinical trials demonstrated a greater risk of priapism. 3. The most effective therapy for ischemic priapism in SCD patients is: a) Hydration. b) Plasmapheresis.
2128
c) Pseudoephedrine tablets. d) Intracavernosal treatments (irrigation and evacuation of corporal blood; injection of alpha-adrenergic sympathomimetic agent). 4. Preventive strategies for stuttering priapism in SCD patients include all of the following EXCEPT: a) Hormonal therapies with gonadotropin-releasing hormone agonist or androgen receptor antagonist. b) Intracavernosal self-injection of phenylephrine. c) Penile prosthesis surgery. d) Polyethylene glycol-modified adenosine deaminase drug therapy. 5. In postpriapism ED patients: a) The only treatment option is penile prosthesis surgery. b) The most common cause is shunt fistula from previous shunt surgery. c) Conservative options (PDE5 inhibitors, vacuum device, intraurethral alprostadil, and intracavernosal injections) can sometimes be effective. d) Corporal fibrosis does not make penile prosthesis surgery more difficult.
Overall evaluation of the activity a. Excellent b. Very good c. Good d. Fair e. Poor
What degree of confidence do you have that you will apply your new learning in your practice? 100% 75% 50% 25% 0%
Was this activity responsive to your needs? Yes No
What one change will you make in your practice based on this new learning?
Was this activity relevant to your practice? Yes No Did this activity increase your knowledge and/or skills in delivering patient care? Yes No
List any topics you would find interesting and professionally relevant for future CME activities: This activity is designed for a maximum of 1 category 1 credit. You should only claim the number of credits you have earned based on the amount of time needed to complete this activity. How many credits are you claiming for this activity? a. 1 b. 0.75 c. 0.5 d. 0.25
Please indicate your current profession: 䊐 Physician 䊐 Nurse 䊐 Physician Assistant 䊐 Other Healthcare Professional 䊐 Nurse Practitioner 䊐 Other
Address 2:
Name:
Postal Code:
Institution:
Country:
Address 1:
Email Address:
City: State:
An online version of this activity is now available. If you wish to receive credit for this activity, please refer to the website: www.wileyblackwellcme.com. Alternatively, this page can be sent by fax to Blackwell Futura Media Services, at (781)-338-8325. If you do not receive your certificate within 30 days of submission, please contact David Kempe, Editorial Program Coordinator, at [email protected].
2128
J Sex Med 2011;8:2128